Voices of Biotech
Podcast: MilliporeSigma says education vital to creating unbreakable chain for sustainability
MilliporeSigma discusses the importance of people, education, and the benefits of embracing discomfort to bolster sustainability efforts.
- Sponsored Content
- Upstream & Downstream Processing
BPI Contributor
September 14, 2021
20 Min View
Date: Sep 14, 2021
Duration: 20 Min
Sponsored by WuXi Advanced Therapies
This webcast features: Dr. Jason King, Business Development Manager, OXGENE
Adenoassociated virus (AAV) is often the vector of choice for gene therapies; in fact, AAV represents around 37% of the current advanced therapies market. And when it comes to manufacturing AAV for in vivo gene therapies, developers must pursue triplicate goals of quality, quantity, and speed.
Here, Dr. Jason King presents the quality, titer, and regulatory advantages of OXGENE’s AAV plasmid system. He discusses the key quality considerations of WuXi Advanced Therapies’ (WuXi ATU) plasmid manufacturing processes, including a real-world example of accelerated manufacture and delivery timelines, before demonstrating the performance of the AAV plasmid system at scale in WuXi ATU’s AAV suspension platform, standardization and optimization of which allows for consistently high results and accelerated time to market.
Key takeaways:
OXGENE’s AAV plasmid system offers higher titers and improved quality compared to industry standard.
WuXi ATU’s world-class plasmid DNA production is antibiotics-free from clone selection, through to banking and manufacture, conferring a significant regulatory advantage.
WuXi ATU’s AAV suspension manufacturing platform delivers consistently high titers in any serotype, at any scale and in any equipment.
This webcast is no longer available.
About the Author(s)
You May Also Like
Upcoming Webcasts
Jun 17 - Jun 20, 2024
Jun 17 - Jun 20, 2024
Our Biopharmaceutical School is the perfect course to gain a well-rounded understanding of the Biopharmaceutical industry. Over three days, you will understand the principle steps in the biopharmaceutical lifecycle, including: raw material selection, up and downstream processes and core technology. Additionally, you will be familiarised with the latest industry trends, including Industry 4.0, and how these are likely to impact the industry’s evolution.
Through a combination of sessions led by experts from the likes of GSK and Pall Biotech, as well as group discussions with your peers, you will learn how to bring a biopharmaceutical drug to market. Each day will be chaired by a different member of the BioProcess International Academy faculty and there will also be time for networking and Q&As with the experts.
Learn More